ENTRADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
ENTRADA THERAPEUTICS, INC. (TRDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 1.28 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-02-26
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-06-30 was 79.20K shares.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-03-31 was 928.29K shares.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-12-31 was 99.52K shares.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-09-30 was 541.42K shares.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 1.28M shares, a 0.81% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 1.29M shares, a 29.95% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 990.17K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 1.28M shares 10-K · filed 2026-02-26 | |||
| 2024-12-31 | 1.29M shares 10-K · filed 2025-02-27 | |||
| 2024-06-30 | 79.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 1.01M shares 10-Q · filed 2024-08-13 | 1.11M shares derived: sum of 3 quarters · filed 2024-08-13 | 1.65M shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 928.29K shares 10-Q · filed 2024-05-07 | 1.03M shares derived: sum of 2 quarters · filed 2024-05-07 | 1.57M shares derived: sum of 3 quarters · filed 2024-05-07 | |
| 2023-12-31 | 99.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 640.95K shares derived: sum of 2 quarters · filed 2024-03-13 | 990.17K shares 10-K · filed 2024-03-13 | |
| 2023-09-30 | 541.42K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 890.65K shares 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | 349.22K shares 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |